A systematic literature review and meta-analysis of clinical outcomes of chikungunya were conducted, analyzing 316 articles. The study found that 90% of patients experienced arthralgia and 88% had fever during the acute phase, which lasts 7–10 days. However, debilitating symptoms can persist for months or years. The overall symptomatic rate was 75% (95% CI: 63–84%), with 44% of symptomatic individuals experiencing chronic symptoms. The mortality rate was 0.3% (95% CI: 0.1–0.7%). The chronicity rate was 43.89% at three months, 34.39% at six months, and 31.87% at twelve months post-infection. Mortality rates were 0.32% for low-risk populations and 15.34% for high-risk populations. The study highlighted the significant clinical burden of chikungunya, with 74.9% of infected individuals experiencing symptoms. Chronic symptoms affect 43.4% of patients and can be debilitating and long-lasting. The study also noted that data gaps remain, with some outcomes not being fully estimated due to limited studies. The findings emphasize the need for further research to better understand the disease and improve public health interventions. The study underscores the importance of early detection and awareness of chikungunya, given its potential for long-term health impacts and the risk of future outbreaks.A systematic literature review and meta-analysis of clinical outcomes of chikungunya were conducted, analyzing 316 articles. The study found that 90% of patients experienced arthralgia and 88% had fever during the acute phase, which lasts 7–10 days. However, debilitating symptoms can persist for months or years. The overall symptomatic rate was 75% (95% CI: 63–84%), with 44% of symptomatic individuals experiencing chronic symptoms. The mortality rate was 0.3% (95% CI: 0.1–0.7%). The chronicity rate was 43.89% at three months, 34.39% at six months, and 31.87% at twelve months post-infection. Mortality rates were 0.32% for low-risk populations and 15.34% for high-risk populations. The study highlighted the significant clinical burden of chikungunya, with 74.9% of infected individuals experiencing symptoms. Chronic symptoms affect 43.4% of patients and can be debilitating and long-lasting. The study also noted that data gaps remain, with some outcomes not being fully estimated due to limited studies. The findings emphasize the need for further research to better understand the disease and improve public health interventions. The study underscores the importance of early detection and awareness of chikungunya, given its potential for long-term health impacts and the risk of future outbreaks.